NASDAQ:ELAB Elevai Labs (ELAB) Stock Price, News & Analysis → Write this ticker symbol down… (From StocksToTrade) (Ad) Free ELAB Stock Alerts $0.64 -0.03 (-4.48%) (As of 05/28/2024 ET) Add Compare Share Share Today's Range$0.64▼$0.6850-Day Range$0.57▼$0.7652-Week Range$0.57▼$4.24Volume249,925 shsAverage Volume322,304 shsMarket Capitalization$12.09 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrendsStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrends Get Elevai Labs alerts: Email Address Ad StocksToTradeWrite this ticker symbol down…A megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made millionaire Tim Bohen is giving you an inside look at the megatrend that’s going to change everything.Discover the #1 company leading this revolution About Elevai Labs Stock (NASDAQ:ELAB)Elevai Labs, Inc., a skincare development company, designs, manufactures, and markets skincare products. Its products include Empower and Enfinity post-skincare procedure care serums for the face, neck, and upper chest regions. The company was formerly known as Reactive Medical Labs Inc. and changed its name to Elevai Labs, Inc. in December 2021. Elevai Labs, Inc. was incorporated in 2020 and is based in Newport Beach, California.Read More ELAB Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ELAB Stock News HeadlinesMay 22, 2024 | finance.yahoo.comElevai Labs Inc Subsidiary, Elevai Biosciences, to Present at the UCLA LA-BEST 2024 ConferenceMay 22, 2024 | globenewswire.comElevai Labs Inc Subsidiary, Elevai Biosciences, to Present at the UCLA LA-BEST 2024 ConferenceMay 16, 2024 | investorplace.comELAB Stock Earnings: Elevai Labs Reported Results for Q1 2024May 15, 2024 | finance.yahoo.comElevai Labs Inc. Reports First Quarter 2024 Financial ResultsMay 2, 2024 | globenewswire.comElevai Biosciences Highlights Preclinical Data Showing Potential of In-Licensed Asset “EL-22” for The Treatment of ObesityMay 1, 2024 | globenewswire.comElevai Labs Expands with Launch of Elevai Biosciences and Elevai Skincare Subsidiaries, Advancing the Future of Aesthetic Medicines and Exosome SkincareMay 1, 2024 | bizjournals.comElevai Labs in deal to develop co-treatments for weight-loss drugsMay 1, 2024 | globenewswire.comElevai Labs Acquires Exclusive License to Two Myostatin Muscle Loss Prevention Assets with Plan to Develop in Combination with GLP-1 Obesity TreatmentsApril 29, 2024 | globenewswire.comElevai Labs Highlights Global Distribution Partnership Overview: Contracts May Secure $4.9M Top Line Revenue CommitmentsApril 25, 2024 | seekingalpha.comELAB Elevai Labs, Inc.April 22, 2024 | globenewswire.comELEVAI Labs Enters the Taiwan Market with Signing of 5th International Distribution Agreement in 14 MonthsApril 20, 2024 | finance.yahoo.comElevai Labs, Inc. (ELAB)April 2, 2024 | investorplace.comELAB Stock Earnings: Elevai Labs Reported Results for Q4 2023March 29, 2024 | globenewswire.comElevai Labs Inc. Reports Record Full Year 2023 and Fourth Quarter Financial ResultsMarch 20, 2024 | investing.comELEVAI launches consumer skincare portalMarch 18, 2024 | globenewswire.comElevai Labs Launches E-commerce Portal to Support Rapid Growth as Stem Cell Exosome Disruptor in the $19.7 Billion Global Physician Dispensed Cosmeceutical MarketFebruary 2, 2024 | finanznachrichten.deFibroBiologics Announces Anticipated Listing DayFebruary 1, 2024 | investorplace.comWhy Is Elevai Labs (ELAB) Stock Up 57% Today?January 24, 2024 | finance.yahoo.comELEVAI Labs Inc. Announces Issuance of Patent from U.S. Patent & Trademark OfficeJanuary 17, 2024 | msn.comELEVAI LABS reports preliminary total net revenue for 2023 of over $1.635MJanuary 17, 2024 | finance.yahoo.comELEVAI LABS, Inc. Reports Strong Preliminary Unaudited Financial Performance for Fiscal Year 2023, Highlighting Significant Revenue Growth and Expanding Global ReachJanuary 16, 2024 | investorplace.comWhy Is Elevai Labs (ELAB) Stock Up Today?January 16, 2024 | finanznachrichten.deElevai Labs Inc.: ELEVAI Labs, Inc. Acquires Worldwide License Agreement for Proprietary Stem Cell Manufacturing TechnologyJanuary 16, 2024 | marketwatch.comElevai Labs Shares Double After Licensing Deal With INmune BioJanuary 2, 2024 | finance.yahoo.comELEVAI LABS, Inc. to Participate in Upcoming Aesthetic Industry ConferencesSee More Headlines Receive ELAB Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Elevai Labs and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/15/2024Today5/29/2024Next Earnings (Estimated)9/26/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:ELAB Previous SymbolNASDAQ:ELAB CUSIPN/A CIK1840563 Webelevaiskincare.com Phone866-794-4940FaxN/AEmployees18Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($0.37) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-4,300,000.00 Net Margins-211.25% Pretax Margin-251.14% Return on Equity-225.32% Return on Assets-125.94% Debt Debt-to-Equity Ratio0.20 Current Ratio2.57 Quick Ratio1.80 Sales & Book Value Annual Sales$1.71 million Price / Sales7.07 Cash FlowN/A Price / Cash FlowN/A Book Value$0.22 per share Price / Book2.91Miscellaneous Outstanding Shares18,890,000Free FloatN/AMarket Cap$12.09 million OptionableN/A BetaN/A 7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleGrowth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.Get This Free Report Key ExecutivesDr. Jordan R. Plews Ph.D. (Age 40)Co-Founder, President, CEO & Director Comp: $200kMs. Brenda Buechler (Age 53)Chief Marketing Officer Comp: $190kMr. Christoph Kraneiss (Age 52)Chief Commercial Officer Comp: $180kDr. Hatem Abou-Sayed F.A.C.S. (Age 52)FACS, M.B.A., M.D., MBA, Co-Founder, Chief Medical Officer & Director Mr. Graydon Bensler C.F.A. (Age 32)CFO, Secretary & Director Key CompetitorsEquilliumNASDAQ:EQEagle PharmaceuticalsNASDAQ:EGRXCASI PharmaceuticalsNASDAQ:CASIOcuphire PharmaNASDAQ:OCUPNabriva TherapeuticsNASDAQ:NBRVView All CompetitorsInstitutional OwnershipDiversify Advisory Services LLCBought 52,500 shares on 5/1/2024Ownership: 0.303%View All Institutional Transactions ELAB Stock Analysis - Frequently Asked Questions How have ELAB shares performed in 2024? Elevai Labs' stock was trading at $1.8282 at the beginning of the year. Since then, ELAB stock has decreased by 65.0% and is now trading at $0.64. View the best growth stocks for 2024 here. Are investors shorting Elevai Labs? Elevai Labs saw a increase in short interest in the month of May. As of May 15th, there was short interest totaling 145,500 shares, an increase of 73.6% from the April 30th total of 83,800 shares. Based on an average daily volume of 174,700 shares, the days-to-cover ratio is currently 0.8 days. View Elevai Labs' Short Interest. When is Elevai Labs' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, September 26th 2024. View our ELAB earnings forecast. How were Elevai Labs' earnings last quarter? Elevai Labs, Inc. (NASDAQ:ELAB) announced its earnings results on Wednesday, May, 15th. The company reported ($0.08) earnings per share for the quarter. The company had revenue of $0.62 million for the quarter. Elevai Labs had a negative net margin of 211.25% and a negative trailing twelve-month return on equity of 225.32%. When did Elevai Labs IPO? Elevai Labs (ELAB) raised $6 million in an IPO on Tuesday, November 21st 2023. The company issued 1,500,000 shares at a price of $4.00 per share. Univest Securities served as the underwriter for the IPO. When did Elevai Labs' lock-up period expire? Elevai Labs' lock-up period expired on Monday, May 20th. Elevai Labs had issued 1,500,000 shares in its IPO on November 21st. The total size of the offering was $6,000,000 based on an initial share price of $4.00. Shares of the company owned by major shareholders and company insiders are now eligible to be traded as a result of the expiration of the lock-up period. Who are Elevai Labs' major shareholders? Elevai Labs' stock is owned by a number of retail and institutional investors. Top institutional investors include Diversify Advisory Services LLC (0.30%). How do I buy shares of Elevai Labs? Shares of ELAB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:ELAB) was last updated on 5/29/2024 by MarketBeat.com Staff From Our PartnersThe #1 Crypto That You Don’t Own… YetCrypto 101 Media4 Cryptos BETTER than BitcoinTrue Market InsidersWrite this ticker symbol down…StocksToTradeMust-See: Elon’s New Invention is Absolutely InsaneInvestorPlaceDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsNvidia is Pivoting to Solve Big Tech’s $1 Trillion ProblemWeiss RatingsBiden replacement revealed?Paradigm PressTop 5 AI Stocks to Buy for 2024Market Moving Trends Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Elevai Labs, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
